MTOR and renal cell carcinoma: Sustained efforts in evaluating inflammatory pathways associated with RCC, mainly focusing on the Von Hippel-Lindau (VHL), mechanistic target of rapamycin (mTOR), tumor necrosis factor (TNF) and STAT pathways [114], have already provided significant insight into oncogenesis and allowed for the development of efficient targeted RCC treatment.